| Year |
Citation |
Score |
| 2023 |
Fukuda Y, Kim SH, Bustos MA, Cho SN, Roszik J, Burks JK, Kim H, Hoon DSB, Grimm EA, Ekmekcioglu S. Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion. Cancer Research Communications. 3: 1397-1408. PMID 37529399 DOI: 10.1158/2767-9764.CRC-23-0210 |
0.305 |
|
| 2022 |
Fukuda Y, Bustos MA, Cho SN, Roszik J, Ryu S, Lopez VM, Burks JK, Lee JE, Grimm EA, Hoon DSB, Ekmekcioglu S. Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death & Disease. 13: 117. PMID 35121729 DOI: 10.1038/s41419-022-04552-y |
0.317 |
|
| 2021 |
Ding Z, Ogata D, Roszik J, Qin Y, Kim SH, Tetzlaff MT, Lazar AJ, Davies MA, Ekmekcioglu S, Grimm EA. iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. Frontiers in Oncology. 11: 631766. PMID 33643925 DOI: 10.3389/fonc.2021.631766 |
0.367 |
|
| 2019 |
Chattopadhyay C, Oba J, Roszik J, Marszalek JR, Chen K, Qi Y, Eterovic K, Robertson AG, Burks JK, McCannel TA, Grimm EA, Woodman SE. Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma. Investigative Ophthalmology & Visual Science. 60: 4187-4195. PMID 31596927 DOI: 10.1167/Iovs.19-28082 |
0.325 |
|
| 2019 |
Roszik J, Markovits E, Dobosz P, Layani A, Slabodnik-Kaner K, Baruch EN, Ben-Betzalel G, Grimm E, Berger R, Sidi Y, Schachter J, Shapira-Frommer R, Avni D, Markel G, Leibowitz-Amit R. TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma. Cancer Immunology, Immunotherapy : Cii. PMID 31501955 DOI: 10.1007/S00262-019-02382-0 |
0.389 |
|
| 2018 |
Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter D, Ekmekcioglu S, Grimm EA. The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30538110 DOI: 10.1158/1078-0432.Ccr-18-1163 |
0.383 |
|
| 2018 |
Dal Yontem F, Kim SH, Ding Z, Grimm E, Ekmekcioglu S, Akcakaya H. Mitochondrial dynamic alterations regulate melanoma cell progression. Journal of Cellular Biochemistry. PMID 30256441 DOI: 10.1002/Jcb.27518 |
0.308 |
|
| 2018 |
Kim SH, Roszik J, Grimm EA, Ekmekcioglu S. Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy. Frontiers in Oncology. 8: 67. PMID 29616189 DOI: 10.3389/Fonc.2018.00067 |
0.36 |
|
| 2017 |
Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, ... ... Grimm EA, et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine. 2. PMID 28819565 DOI: 10.1038/S41525-017-0013-8 |
0.306 |
|
| 2017 |
Qin Y, Conley AP, Grimm EA, Roszik J. A tool for discovering drug sensitivity and gene expression associations in cancer cells. Plos One. 12: e0176763. PMID 28453553 DOI: 10.1371/Journal.Pone.0176763 |
0.322 |
|
| 2017 |
Maturu P, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, Putluri N, Ekmekcioglu S, Grimm EA, Dong C, Overwijk WW. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia (New York, N.Y.). 19: 237-249. PMID 28254151 DOI: 10.1016/J.Neo.2016.07.009 |
0.477 |
|
| 2017 |
Ekmekcioglu S, Grimm EA, Roszik J. Targeting iNOS to increase efficacy of immunotherapies. Human Vaccines & Immunotherapeutics. 0. PMID 28121247 DOI: 10.1080/21645515.2016.1276682 |
0.406 |
|
| 2017 |
Oba J, Esmaeli B, Ellerhorst JA, Lyons GR, Milton DR, Wang WL, Macedo MP, Lazar AJ, Grimm EA, Chattopadhyay C. Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression. Melanoma Research. PMID 28118269 DOI: 10.1097/Cmr.0000000000000329 |
0.308 |
|
| 2017 |
Roszik J, Qin Y, Ekmekcioglu S, Forget M, Hwu P, Grimm EA, Jazaeri AA. The neoantigen landscape and immune regulators in cervical cancer. Journal of Clinical Oncology. 35: 5528-5528. DOI: 10.1200/Jco.2017.35.15_Suppl.5528 |
0.315 |
|
| 2017 |
Leibowitz-Amit R, Roszik J, Avni D, Grimm E. Abstract 5602: Regulation of immune checkpoint genes revealed by a melanoma tumor cancer genome atlas (TCGA) analysis - potential implications for improving immunotherapy Cancer Research. 77: 5602-5602. DOI: 10.1158/1538-7445.Am2017-5602 |
0.309 |
|
| 2017 |
Kim S, Roszik J, Peng W, Ekmekcioglu S, Grimm EA. Abstract 3967: High microsomal PGE2synthase-1 levels associate with low CD8 T cells and poorer melanoma patient survival Cancer Research. 77: 3967-3967. DOI: 10.1158/1538-7445.Am2017-3967 |
0.303 |
|
| 2016 |
Bailey P, Chang DK, Forget MA, Lucas FA, Alvarez HA, Haymaker C, Chattopadhyay C, Kim SH, Ekmekcioglu S, Grimm EA, Biankin AV, Hwu P, Maitra A, Roszik J. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports. 6: 35848. PMID 27762323 DOI: 10.1038/Srep35848 |
0.371 |
|
| 2016 |
Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, Overwijk WW, Roszik J, Marincola FM, Hwu P, Grimm EA, Radvanyi LG. IL-2 variant circumvents ICOS+ regulatory T cell expansion and promotes NK cell activation. Cancer Immunology Research. PMID 27697858 DOI: 10.1158/2326-6066.Cir-15-0195 |
0.458 |
|
| 2016 |
Grimm EA. Immunology Comes Full Circle in Melanoma While Specific Immunity Is Unleashed to Eliminate Metastatic Disease, Inflammatory Products of Innate Immunity Promote Resistance. Critical Reviews in Oncogenesis. 21: 57-63. PMID 27481002 DOI: 10.1615/Critrevoncog.2016016901 |
0.38 |
|
| 2016 |
Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EA. Hypoxia-driven mechanism of vemurafenib resistance in melanoma. Molecular Cancer Therapeutics. PMID 27458138 DOI: 10.1158/1535-7163.Mct-15-0963 |
0.339 |
|
| 2016 |
Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer. PMID 26991400 DOI: 10.1002/Cncr.29727 |
0.321 |
|
| 2016 |
Kim SH, Hashimoto Y, Cho SN, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell & Melanoma Research. PMID 26801201 DOI: 10.1111/Pcmr.12455 |
0.442 |
|
| 2016 |
Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26783288 DOI: 10.1158/1078-0432.Ccr-15-2226 |
0.385 |
|
| 2016 |
Chakravarti N, Sui D, Milton DR, Hwu W, Grimm EA, Prieto VG. Abstract 3570: Differential expression of the melanoma inhibitor of apoptosis protein (ML-IAP)/Livin in patients with ulcerated and non-ulcerated melanomas Cancer Research. 76: 3570-3570. DOI: 10.1158/1538-7445.Am2016-3570 |
0.415 |
|
| 2016 |
Kim S, Hashimoto Y, Cho S, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA. Abstract 2285: Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression Cancer Research. 76: 2285-2285. DOI: 10.1158/1538-7445.Am2016-2285 |
0.446 |
|
| 2016 |
Ding Z, Qin Y, Kim S, Grimm EA. Nitric Oxide Activates the PI3Kinase-Akt Pathway in Human Melanoma Cells Free Radical Biology and Medicine. 100: S120. DOI: 10.1016/J.Freeradbiomed.2016.10.310 |
0.438 |
|
| 2015 |
Chan IH, Wu V, McCauley S, Grimm EA, Mumm JB. IL-10: Expanding the Immune Oncology Horizon. Receptors & Clinical Investigation. 2. PMID 26661378 DOI: 10.14800/Rci.1041 |
0.747 |
|
| 2015 |
Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, et al. Dual Roles of RNF2 in Melanoma Progression. Cancer Discovery. PMID 26450788 DOI: 10.1158/2159-8290.Cd-15-0493 |
0.38 |
|
| 2015 |
Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ. The Journal of Investigative Dermatology. PMID 26178706 DOI: 10.1038/Jid.2015.259 |
0.303 |
|
| 2015 |
Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ. The Journal of Investigative Dermatology. 135: 2775-84. PMID 26039541 DOI: 10.1038/Jid.2015.204 |
0.442 |
|
| 2015 |
Qin Y, Milton DR, Oba J, Ding Z, Lizée G, Ekmekcioglu S, Grimm EA. Inflammatory IL-1β-driven JNK activation in stage III melanoma. Pigment Cell & Melanoma Research. 28: 236-9. PMID 25546243 DOI: 10.1111/Pcmr.12348 |
0.365 |
|
| 2015 |
Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SE. Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell & Melanoma Research. 28: 357-9. PMID 25515650 DOI: 10.1111/Pcmr.12345 |
0.316 |
|
| 2015 |
Oba J, Chattopadhyay C, Gershenwald JE, Johnson MM, Ellerhorst JA, Grimm EA. Abstract A32: A role for elevated leptin, independent of obesity, in the progression of melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-A32 |
0.32 |
|
| 2015 |
Chattopadhyay C, Oba J, Esmaeli B, Ellerhorst JA, Grimm EA. Abstract A27: Analyses of the level of liver borne growth factors, IGF-1 and HGF in metastatic and non-metastatic uveal melanoma patient serum: Correlation with outcome Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-A27 |
0.318 |
|
| 2014 |
Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Translational Oncology. 7: 484-92. PMID 24969538 DOI: 10.1016/J.Tranon.2014.05.008 |
0.409 |
|
| 2014 |
Chattopadhyay C, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. Plos One. 9: e83957. PMID 24551032 DOI: 10.1371/Journal.Pone.0083957 |
0.355 |
|
| 2014 |
Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso J, Sikora AG. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Research. 74: 1067-78. PMID 24398473 DOI: 10.1158/0008-5472.Can-13-0588 |
0.45 |
|
| 2014 |
Kim S, Hashimoto Y, Ekmekcioglu S, Grimm EA. Abstract 4200: Interaction between mPGES-1 and iNOS promotes human melanoma progression Cancer Research. 74: 4200-4200. DOI: 10.1158/1538-7445.Am2014-4200 |
0.479 |
|
| 2014 |
Ding Z, Qin Y, Wiktorowicz JE, Grimm EA. Quantitative protein S-nitrosation proteomic profiling in human melanoma cells by a novel fluorescence based detection and analysis Nitric Oxide. 42: 120. DOI: 10.1016/J.Niox.2014.09.065 |
0.304 |
|
| 2013 |
Grimm EA, Sikora AG, Ekmekcioglu S. Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5557-63. PMID 23868870 DOI: 10.1158/1078-0432.Ccr-12-1554 |
0.371 |
|
| 2013 |
Qin Y, Deng W, Ekmekcioglu S, Grimm EA. Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening. Pigment Cell & Melanoma Research. 26: 97-112. PMID 23020131 DOI: 10.1111/Pcmr.12031 |
0.396 |
|
| 2013 |
Sim GC, Grimm E, Dai Z, Overwijk W, Hwu P, Radvanyi L. IL-2 analogues: novel agents circumventing the expansion of T regulatory cells while promoting NK cell activation during IL-2 therapy Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P89 |
0.457 |
|
| 2013 |
Qin Y, Greene VR, Chattopadhyay C, Ekmekcioglu S, Liu C, Grimm EA. Abstract 2936: Induction of hypoxia in 3D human melanoma spheroids leads to c-Met activation and resistance to Vemurafenib. Cancer Research. 73: 2936-2936. DOI: 10.1158/1538-7445.Am2013-2936 |
0.388 |
|
| 2012 |
Khalili JS, Liu S, RodrÃguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5329-40. PMID 22850568 DOI: 10.1158/1078-0432.Ccr-12-1632 |
0.431 |
|
| 2012 |
Shirley SH, Grimm EA, Kusewitt DF. Ultraviolet radiation and the slug transcription factor induce proinflammatory and immunomodulatory mediator expression in melanocytes. Journal of Skin Cancer. 2012: 410925. PMID 22745913 DOI: 10.1155/2012/410925 |
0.414 |
|
| 2012 |
Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. Plos One. 7: e34833. PMID 22558101 DOI: 10.1371/Journal.Pone.0034833 |
0.359 |
|
| 2012 |
Shirley SH, Greene VR, Duncan LM, Torres Cabala CA, Grimm EA, Kusewitt DF. Slug expression during melanoma progression. The American Journal of Pathology. 180: 2479-89. PMID 22503751 DOI: 10.1016/J.Ajpath.2012.02.014 |
0.39 |
|
| 2012 |
Lee I, Fox PS, Ferguson SD, Bassett R, Kong LY, Schacherer CW, Gershenwald JE, Grimm EA, Fuller GN, Heimberger AB. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget. 3: 336-44. PMID 22488042 DOI: 10.18632/Oncotarget.475 |
0.365 |
|
| 2012 |
Jen EY, Poindexter NJ, Farnsworth ES, Grimm EA. IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells. Melanoma Research. 22: 19-29. PMID 22027907 DOI: 10.1097/Cmr.0B013E32834D2506 |
0.439 |
|
| 2012 |
Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of activated c-Met with NRAS-mutated human melanomas. International Journal of Cancer. 131: E56-65. PMID 22020736 DOI: 10.1002/Ijc.26487 |
0.361 |
|
| 2012 |
Tanese K, Grimm EA, Ekmekcioglu S. The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10. International Journal of Cancer. 131: 891-901. PMID 21953496 DOI: 10.1002/Ijc.26451 |
0.457 |
|
| 2012 |
Qin Y, Kwon J, Li L, Rosenblatt KP, Zhang S, Chen L, Jayachandran G, Grimm EA. Abstract 4988: The S-nitrosylation-mediated modification of p53 leads to altered DNA binding and associates with inactivity of p53 in human melanoma cells Cancer Research. 72: 4988-4988. DOI: 10.1158/1538-7445.Am2012-4988 |
0.401 |
|
| 2012 |
Ekmekcioglu S, Qin Y, Deng W, Grimm EA. Abstract 1833: A large-scale synthetic lethal RNAi screening identifies unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma Cancer Research. 72: 1833-1833. DOI: 10.1158/1538-7445.Am2012-1833 |
0.477 |
|
| 2012 |
Tanese K, Grimm E, Ekmekcioglu S. 839 Nitric Oxide Suppresses the Expression of CXCL10 and Leads to the Poor Outcome of Stage III Malignant Melanoma European Journal of Cancer. 48: S201. DOI: 10.1016/S0959-8049(12)71472-7 |
0.32 |
|
| 2012 |
Ekmekcioglu S, Tanese K, Qin Y, Grimm EA. NO-Driven Inflammation in Human Melanoma via IL-1s and CXCL-10 Free Radical Biology and Medicine. 53: S181. DOI: 10.1016/J.Freeradbiomed.2012.10.498 |
0.399 |
|
| 2012 |
Qin Y, Kwon J, Li L, Rosenblatt KP, Jayachandran G, Zhang S, Grimm EA. The S-Nitrosylation of P53 Leads to Altered DNA Binding and Downstream Gene Expression in Human Melanoma Cells Free Radical Biology and Medicine. 53: S49. DOI: 10.1016/J.Freeradbiomed.2012.10.131 |
0.333 |
|
| 2011 |
Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Lizée G, Poindexter N, Grimm EA. Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Molecular Cancer Research : McR. 9: 1537-50. PMID 21954434 DOI: 10.1158/1541-7786.Mcr-11-0279 |
0.472 |
|
| 2011 |
Ekmekcioglu S, Chattopadhyay C, Akar U, Gabisi A, Newman RA, Grimm EA. Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells. Nutrition and Cancer. 63: 940-9. PMID 21745040 DOI: 10.1080/01635581.2011.586488 |
0.397 |
|
| 2011 |
Shanker M, Jin J, Branch CD, Miyamoto S, Grimm EA, Roth JA, Ramesh R. Tumor suppressor gene-based nanotherapy: from test tube to the clinic. Journal of Drug Delivery. 2011: 465845. PMID 21490751 DOI: 10.1155/2011/465845 |
0.347 |
|
| 2011 |
Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 229-35. PMID 20975100 DOI: 10.1158/1078-0432.Ccr-10-2276 |
0.313 |
|
| 2011 |
Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EA. IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Research. 21: 44-56. PMID 20216471 DOI: 10.1097/Cmr.0B013E3283382155 |
0.532 |
|
| 2011 |
Huerta-Yepez S, Ekmekcioglu S, Rivera-Pazos CM, Antonio-Andres G, Vega MI, Baay-Guzman G, Grimm E. Braf Mutations Are Associated With High Levels of Phosphorylated RKIP in Melanoma Cell Lines: Potential Prognostic Significance Forum On Immunopathological Diseases and Therapeutics. 2: 189-194. DOI: 10.1615/Forumimmundisther.V2.I2.100 |
0.325 |
|
| 2011 |
Qin Y, Ekmekcioglu S, Liu P, Poindexter N, Grimm EA. Abstract 5051: Aberrant endogenous expression of IL-1 promote inflammation and growth in human melanoma Cancer Research. 71: 5051-5051. DOI: 10.1158/1538-7445.Am2011-5051 |
0.439 |
|
| 2011 |
Tanese K, Ekmekcioglu S, Grimm E. Abstract 401: Inducible nitric oxide synthase suppresses the expression of CXCL10 and hence leads to the poor outcome of Stage III malignant melanoma Cancer Research. 71: 401-401. DOI: 10.1158/1538-7445.Am2011-401 |
0.488 |
|
| 2010 |
Poindexter NJ, Williams RR, Powis G, Jen E, Caudle AS, Chada S, Grimm EA. IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes. Experimental Dermatology. 19: 714-22. PMID 20545760 DOI: 10.1111/J.1600-0625.2010.01077.X |
0.437 |
|
| 2010 |
Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1834-44. PMID 20215556 DOI: 10.1158/1078-0432.Ccr-09-3123 |
0.4 |
|
| 2010 |
Ellerhorst JA, Diwan AH, Dang SM, Uffort DG, Johnson MK, Cooke CP, Grimm EA. Promotion of melanoma growth by the metabolic hormone leptin. Oncology Reports. 23: 901-7. PMID 20204272 DOI: 10.3892/Or_00000713 |
0.403 |
|
| 2010 |
Lizee G, Whittington MA, Chen J, Greene VR, Liu S, Bassett RL, Khalili J, Prieto V, Radvanyi LG, Hwu P, Grimm EA, Gershenwald JE. Correlation of prevalence of CD68+ macrophages within tumor-draining lymph node basins and overall survival in stage III melanoma patients. Journal of Clinical Oncology. 28: e21034-e21034. DOI: 10.1200/Jco.2010.28.15_Suppl.E21034 |
0.362 |
|
| 2010 |
Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Grimm EA. Abstract 5456: Preferential targeting of N-Ras mutant and other wild type B-Raf human melanoma cells with c-Met inhibitor: a preclinical promise Cancer Research. 70: 5456-5456. DOI: 10.1158/1538-7445.Am10-5456 |
0.368 |
|
| 2010 |
Qin Y, Ekmekcioglu S, Poindexter N, Ellerhorst J, Grimm EA. Abstract 4506: Elevated expression of IL-1 induces iNOS/NO production and inhibits IL-1Ra synthesis leading to progression of metastatic melanoma Cancer Research. 70: 4506-4506. DOI: 10.1158/1538-7445.Am10-4506 |
0.446 |
|
| 2010 |
Ahmed KBR, Garcia-Prieto C, Feng L, Grimm EA, Jin Z, Huang P. Abstract 3567: The antitumor agent OSW-1 in melanoma therapy : An insight Cancer Research. 70: 3567-3567. DOI: 10.1158/1538-7445.Am10-3567 |
0.424 |
|
| 2010 |
Deng W, Poindexter NJ, Ekmekcioglu S, Kwon J, Kinney SA, Grimm EA. Abstract 2564: High-throughput siRNA library screen for discovery and identification of new melanoma therapeutic targets in combination with antioxidant pretreatment Cancer Research. 70: 2564-2564. DOI: 10.1158/1538-7445.Am10-2564 |
0.386 |
|
| 2010 |
Huerta-Yepez S, Suhendan E, Antonio-Andres G, Rivera-Pazos CM, Baay-Guzman G, Vega MI, Malaponte G, Jazirehi A, Baritaki S, Grimm E, Bonavida B. Abstract 2242: Correlation between the overexpression of the metastasis-inducer transcription factors Snail and Yin Yang 1 andBRAFmutations in a large panel of melanoma cell lines Cancer Research. 70: 2242-2242. DOI: 10.1158/1538-7445.Am10-2242 |
0.409 |
|
| 2010 |
Deng W, Ekmekcioglu S, Ellerhorst JA, Poindexter NJ, Kwon J, Kinney SA, Grimm EA. Abstract 1175: PCR array-based gene expression profiling identifies CD70 and CD74 as molecular markers and potential therapeutic targets for human melanoma Cancer Research. 70: 1175-1175. DOI: 10.1158/1538-7445.Am10-1175 |
0.407 |
|
| 2009 |
Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunology, Immunotherapy : Cii. 58: 1023-32. PMID 19002459 DOI: 10.1007/S00262-008-0618-Y |
0.393 |
|
| 2009 |
Uffort DG, Grimm EA, Ellerhorst JA. NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. The Journal of Investigative Dermatology. 129: 148-54. PMID 18668140 DOI: 10.1038/Jid.2008.205 |
0.392 |
|
| 2008 |
Zheng M, Bocangel D, Ramesh R, Ekmekcioglu S, Poindexter N, Grimm EA, Chada S. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Molecular Cancer Therapeutics. 7: 3842-51. PMID 19056673 DOI: 10.1158/1535-7163.Mct-08-0516 |
0.503 |
|
| 2008 |
Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5759-68. PMID 18794085 DOI: 10.1158/1078-0432.Ccr-08-0377 |
0.368 |
|
| 2008 |
Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Research. 18: 241-5. PMID 18626307 DOI: 10.1097/Cmr.0B013E3283046146 |
0.378 |
|
| 2008 |
Ekmekcioglu S, Mumm JB, Udtha M, Chada S, Grimm EA. Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. Cytokine. 43: 34-44. PMID 18511292 DOI: 10.1016/J.Cyto.2008.04.010 |
0.777 |
|
| 2008 |
Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S. Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 19: 133-7. PMID 18472017 DOI: 10.1016/J.Niox.2008.04.009 |
0.79 |
|
| 2007 |
Li C, Hu Z, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer. 109: 1570-8. PMID 17328085 DOI: 10.1002/Cncr.22582 |
0.322 |
|
| 2007 |
Zheng M, Priebe W, Walch ET, Roth KG, Han M, Tang CH, Lee S, Poindexter NJ, Fokt I, Grimm EA. WP760, a melanoma selective drug. Cancer Chemotherapy and Pharmacology. 60: 625-33. PMID 17195067 DOI: 10.1007/S00280-006-0404-5 |
0.726 |
|
| 2007 |
Zheng M, Bocangel D, Doneske B, Mhashilkar A, Ramesh R, Hunt KK, Ekmekcioglu S, Sutton RB, Poindexter N, Grimm EA, Chada S. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10 Cancer Immunology, Immunotherapy. 56: 205-215. PMID 16710719 DOI: 10.1007/S00262-006-0175-1 |
0.457 |
|
| 2007 |
Li C, Lu J, Hu Z, Liu Z, Wang L, Sturgis E, El-Naggar A, Prieto V, Gershenwald J, Lee J, Grimm E, Wei Q. A Functional Six-Nucletide Insertion/Deletion Polymorphism in the CASP8 Promoter Region Protects Against Cutaneous Melanoma and Squamous Cell Carcinoma of Head and Neck Annals of Epidemiology. 17: 753. DOI: 10.1016/J.Annepidem.2007.07.089 |
0.313 |
|
| 2006 |
Mumm JB, Ekmekcioglu S, Poindexter NJ, Chada S, Grimm EA. Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 26: 877-86. PMID 17238830 DOI: 10.1089/Jir.2006.26.877 |
0.757 |
|
| 2006 |
Hwu P, Bedikian AY, Grimm EA. Challenges of chemosensitivity testing. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5258-9. PMID 17000655 DOI: 10.1158/1078-0432.Ccr-06-1656 |
0.314 |
|
| 2006 |
Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology. 8: 261-79. PMID 16775224 DOI: 10.1215/15228517-2006-008 |
0.354 |
|
| 2006 |
Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. International Journal of Cancer. 119: 861-6. PMID 16557582 DOI: 10.1002/Ijc.21767 |
0.382 |
|
| 2006 |
Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene. 25: 3956-62. PMID 16474847 DOI: 10.1038/Sj.Onc.1209419 |
0.441 |
|
| 2006 |
Zheng M, Bocangel D, Mhashilkar A, Ramesh R, Hunt KK, Ekmekcioglu S, Poindexter N, Grimm EA, Chada S. 771. Human mda-7/Interleukin 24 (IL-24) Protein Kills Breast Cancer Cells Via the IL-20 Receptor and Is Antagonized by IL-10 Molecular Therapy. 13: S298. DOI: 10.1016/J.Ymthe.2006.08.857 |
0.452 |
|
| 2006 |
Grimm E, Ekmekcioglu S, Tang C, Prieto V. O51. Endogenous nitric oxide in human melanoma supports tumor cell growth and resistance to chemotherapeutic agents Nitric Oxide. 14: 15-16. DOI: 10.1016/J.Niox.2006.04.055 |
0.76 |
|
| 2005 |
Poindexter NJ, Walch ET, Chada S, Grimm EA. Cytokine induction of interleukin-24 in human peripheral blood mononuclear cells. Journal of Leukocyte Biology. 78: 745-52. PMID 16000394 DOI: 10.1189/Jlb.0205116 |
0.431 |
|
| 2005 |
Chada S, Bocangel D, Ramesh R, Grimm EA, Mumm JB, Mhashilkar AM, Zheng M. mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 724-33. PMID 15851011 DOI: 10.1016/J.Ymthe.2004.12.021 |
0.78 |
|
| 2005 |
Ekmekcioglu S, Tang CH, Grimm EA. NO news is not necessarily good news in cancer. Current Cancer Drug Targets. 5: 103-15. PMID 15810875 DOI: 10.2174/1568009053202072 |
0.764 |
|
| 2005 |
Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 160-72. PMID 15585417 DOI: 10.1016/J.Ymthe.2004.09.021 |
0.464 |
|
| 2005 |
Chada S, Bocangel D, Rajagopal R, Grimm E, Mhashilkar AM, Zheng M. 809. mda-7 Kills Pancreatic Cancer Cells by Inhibition of Wnt/PI3K Signaling: Identification of IL-20 Receptor-Mediated Bystander Activity Against Pancreatic Cancer Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.346 |
0.493 |
|
| 2004 |
Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D, Zheng M, Grimm EA, Ekmekcioglu S. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 1085-95. PMID 15564140 DOI: 10.1016/J.Ymthe.2004.08.020 |
0.766 |
|
| 2004 |
Ellerhorst JA, Naderi AA, Johnson MK, Pelletier P, Prieto VG, Diwan AH, Johnson MM, Gunn DC, Yekell S, Grimm EA. Expression of thyrotropin-releasing hormone by human melanoma and nevi. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5531-6. PMID 15328193 DOI: 10.1158/1078-0432.Ccr-03-0368 |
0.406 |
|
| 2004 |
Poindexter NJ, Sahin A, Hunt KK, Grimm EA. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Research : Bcr. 6: R408-15. PMID 15217509 DOI: 10.1186/Bcr808 |
0.362 |
|
| 2004 |
Zheng M, Ekmekcioglu S, Walch ET, Tang CH, Grimm EA. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Research. 14: 165-71. PMID 15179184 DOI: 10.1097/01.Cmr.0000129374.76399.19 |
0.785 |
|
| 2004 |
Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, Poìndexter N, Roth JA, Ramesh R, Grimm EA, Mhashilkar AM. MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. International Immunopharmacology. 4: 649-67. PMID 15120650 DOI: 10.1016/J.Intimp.2004.01.017 |
0.771 |
|
| 2004 |
Sieger KA, Mhashilkar AM, Stewart A, Sutton RB, Strube RW, Chen SY, Pataer A, Swisher SG, Grimm EA, Ramesh R, Chada S. The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells Molecular Therapy. 9: 355-367. PMID 15006602 DOI: 10.1016/J.Ymthe.2003.11.014 |
0.488 |
|
| 2004 |
Tang CH, Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. The Journal of Biological Chemistry. 279: 288-98. PMID 14576150 DOI: 10.1074/jbc.M310821200 |
0.756 |
|
| 2004 |
Poindexter N, Murray J, Grimm E. Melanoma Specific T Cells Identified in the Peripheral Blood of Durable Responders to Biochemotherapy Journal of Immunotherapy. 27: S16. DOI: 10.1097/00002371-200411000-00061 |
0.307 |
|
| 2004 |
Chada S, Mhashilkar A, Ramesh R, Mumm JB, Bocangel D, Grimm EA, Ekmekcioglu S. 955. Bystander Activity of Ad-mda7: MDA-7 Protein Kills Melanoma Cells Via a Receptor-Dependent but STAT3-Independent Mechanism Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.898 |
0.434 |
|
| 2003 |
Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA, Rosenfeld MR, Curiel DT, Dent P. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biology & Therapy. 2: S23-37. PMID 14508078 DOI: 10.4161/Cbt.458 |
0.507 |
|
| 2003 |
Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K, Mumm JB, Stewart AL, Boquoi A, Dumoutier L, Grimm EA, Renauld JC, Kotenko S, Chada S, Boquio A. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Research. 63: 5105-13. PMID 12941841 |
0.747 |
|
| 2003 |
Mhashilkar AM, Stewart AL, Sieger K, Yang HY, Khimani AH, Ito I, Saito Y, Hunt KK, Grimm EA, Roth JA, Meyn RE, Ramesh R, Chada S. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 8: 207-19. PMID 12907143 DOI: 10.1016/S1525-0016(03)00170-9 |
0.395 |
|
| 2003 |
Ellerhorst JA, Cooksley CD, Broemeling L, Johnson MM, Grimm EA. High prevalence of hypothyroidism among patients with cutaneous melanoma Oncology Reports. 10: 1317-1320. PMID 12883700 DOI: 10.3892/Or.10.5.1317 |
0.306 |
|
| 2003 |
Ekmekcioglu S, Ellerhorst JA, Mumm JB, Zheng M, Broemeling L, Prieto VG, Stewart AL, Mhashilkar AM, Chada S, Grimm EA. Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Molecular Cancer Therapeutics. 2: 9-17. PMID 12533668 |
0.736 |
|
| 2002 |
Stewart AL, Mhashilkar AM, Yang XH, Ekmekcioglu S, Saito Y, Sieger K, Schrock R, Onishi E, Swanson X, Mumm JB, Zumstein L, Watson GJ, Snary D, Roth JA, Grimm EA, et al. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Molecular Medicine (Cambridge, Mass.). 8: 451-61. PMID 12435856 |
0.727 |
|
| 2002 |
Lee JE, Abdalla J, Porter GA, Bradford L, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MI. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Annals of Surgical Oncology. 9: 587-93. PMID 12095976 DOI: 10.1007/Bf02573896 |
0.324 |
|
| 2002 |
Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S, Grimm EA. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. Journal of Immunology (Baltimore, Md. : 1950). 168: 6041-6. PMID 12055212 DOI: 10.4049/Jimmunol.168.12.6041 |
0.749 |
|
| 2002 |
Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, Grimm EA. Loss of MDA-7 expression with progression of melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1069-74. PMID 11844832 DOI: 10.1200/Jco.20.4.1069 |
0.445 |
|
| 2002 |
Stewart AL, Mhashilkar AM, Yang XH, Ekmekcioglu S, Saito Y, Sieger K, Schrock R, Onishi E, Swanson X, Mumm JB, Zumstein L, Watson GJ, Snary D, Roth JA, Grimm EA, et al. PI3K Blockade by Ad-PTEN Inhibits Invasion and Induces Apoptosis in Radial Growth Phase and Metastatic Melanoma Cells Molecular Medicine. 8: 451-461. DOI: 10.1007/Bf03402025 |
0.755 |
|
| 2001 |
Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, Chada S, Grimm EA. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. International Journal of Cancer. 94: 54-9. PMID 11668478 DOI: 10.1002/Ijc.1437 |
0.467 |
|
| 2001 |
Mehta SK, Kaur I, Grimm EA, Smid C, Feeback DL, Pierson DL. Decreased non-MHC-restricted (CD56+) killer cell cytotoxicity after spaceflight. Journal of Applied Physiology (Bethesda, Md. : 1985). 91: 1814-8. PMID 11568167 DOI: 10.1152/Jappl.2001.91.4.1814 |
0.31 |
|
| 2001 |
Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, Ross MI, Mansfield PF, Gershenwald JE, Lee JE. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Annals of Surgical Oncology. 8: 116-22. PMID 11258775 DOI: 10.1007/S10434-001-0116-3 |
0.392 |
|
| 2000 |
Caudell EG, Caudell JJ, Tang CH, Yu TK, Frederick MJ, Grimm EA. Characterization of human copine III as a phosphoprotein with associated kinase activity. Biochemistry. 39: 13034-43. PMID 11041869 DOI: 10.1021/Bi001250V |
0.76 |
|
| 2000 |
Yu TK, Caudell EG, Smid C, Grimm EA. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. Journal of Immunology (Baltimore, Md. : 1950). 164: 6244-51. PMID 10843677 DOI: 10.4049/Jimmunol.164.12.6244 |
0.734 |
|
| 1999 |
Ekmekcioglu S, Okcu MF, Colome-Grimmer MI, Owen-Schaub L, Buzaid AC, Grimm EA. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10. Melanoma Research. 9: 261-72. PMID 10465582 DOI: 10.1097/00008390-199906000-00008 |
0.453 |
|
| 1998 |
Robinson EK, Grau AM, Evans DB, Smid CM, Chiao PJ, Abbruzzese JL, Grimm EA. Cell cycle regulation of human pancreatic cancer by tamoxifen. Annals of Surgical Oncology. 5: 342-9. PMID 9641456 DOI: 10.1007/Bf02303498 |
0.343 |
|
| 1998 |
Anderson CM, Buzaid AC, Sussman J, Lee JJ, Ali-Osman F, Braunschweiger PG, Plager C, Bedikian A, Papadopoulos N, Eton O, Legha SS, Grimm EA. Nitric oxide and neopterin levels and clinical response in stage iii melanoma patients receiving concurrent biochemotherapy Melanoma Research. 8: 149-155. PMID 9610868 DOI: 10.1097/00008390-199804000-00008 |
0.317 |
|
| 1997 |
Frederick M, Grimm E, Krohn E, Smid C, Yu TK. Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 17: 435-47. PMID 9282823 DOI: 10.1089/Jir.1997.17.435 |
0.7 |
|
| 1997 |
Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S. Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study. Journal of Immunotherapy (Hagerstown, Md. : 1997). 20: 79-87. PMID 9101417 DOI: 10.1097/00002371-199701000-00009 |
0.353 |
|
| 1997 |
Anderson CM, Buzaid AC, Grimm EA. Interaction of chemotherapy and biological response modifiers in the treatment of melanoma. Cancer Treatment and Research. 87: 357-80. PMID 8886461 DOI: 10.1007/978-1-4613-1267-3_15 |
0.384 |
|
| 1997 |
Anderson C, Buzaid A, Sussman J, Lee J, Legha S, Grimm E. Nitric oxide (NO), neopterin, and cytokine levels versus clinical response in stage III melanoma patients receiving concurrent biochemotherapy Melanoma Research. 7: S112. DOI: 10.1097/00008390-199706001-00390 |
0.314 |
|
| 1996 |
Frederick MJ, Yu TK, Krohn EG, Johnston DA, Grimm EA. Protein tyrosine kinase inhibition blocks granule exocytosis and cytolytic function of lymphokine-activated killer cells. Immunopharmacology. 35: 83-102. PMID 8956972 DOI: 10.1016/S0162-3109(96)00115-4 |
0.709 |
|
| 1996 |
Francis GM, Krohn EG, Woods KV, Buzaid AC, Grimm EA. Interleukin-6 production and secretion in human melanoma cell lines: regulation by interleukin-1. Melanoma Research. 6: 191-201. PMID 8819122 DOI: 10.1097/00008390-199606000-00002 |
0.422 |
|
| 1996 |
Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clinical and Experimental Immunology. 105: 344-52. PMID 8706344 DOI: 10.1046/J.1365-2249.1996.D01-753.X |
0.41 |
|
| 1995 |
Heaton KM, Grimm EA. Differential inhibition of lymphokine-activated killing, proliferation, and cytokine secretion by humanized antibodies against the low- and intermediate-affinity interleukin-2 receptors. A novel model for activation of human peripheral blood mononuclear cells by interleukin 2. Human Immunology. 42: 274-80. PMID 7759316 DOI: 10.1016/0198-8859(94)00106-Z |
0.431 |
|
| 1995 |
Roussel E, Gingras MC, Grimm EA, Roth JA. High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma. Cancer Immunology, Immunotherapy : Cii. 41: 1-9. PMID 7641214 DOI: 10.1007/Bf01788953 |
0.413 |
|
| 1995 |
Tyler DS, Francis GM, Frederick M, Tran AH, Ordóñez NG, Smith JL, Eton O, Ross M, Grimm EA. Interleukin-1 production in tumor cells of human melanoma surgical specimens. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 15: 331-40. PMID 7627808 DOI: 10.1089/Jir.1995.15.331 |
0.468 |
|
| 1994 |
Fujiwara T, Grimm EA, Roth JA. Gene therapeutics and gene therapy for cancer. Current Opinion in Oncology. 6: 96-105. PMID 8204698 DOI: 10.1097/00001622-199401000-00014 |
0.354 |
|
| 1994 |
Fujiwara T, Mukhopadhyay T, Cai DW, Morris DK, Roth JA, Grimm EA. Retroviral-mediated transduction of p53 gene increases TGF-beta expression in a human glioblastoma cell line. International Journal of Cancer. 56: 834-9. PMID 8119773 DOI: 10.1002/Ijc.2910560614 |
0.314 |
|
| 1994 |
Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. Journal of the National Cancer Institute. 86: 1458-62. PMID 8089864 DOI: 10.1093/Jnci/86.19.1458 |
0.32 |
|
| 1994 |
Buzald AC, Grimm EA, Ali-Osman F, Ring S, Eton O, Papadopoulos NE, Bedikian A, Plager C, Legha SS, Benjamin R. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: Preliminary results Melanoma Research. 4: 327-330. PMID 7858418 DOI: 10.1097/00008390-199410000-00010 |
0.396 |
|
| 1994 |
Heaton KM, Ju G, Grimm EA. Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs. Annals of Surgical Oncology. 1: 198-203. PMID 7842289 DOI: 10.1007/Bf02303524 |
0.454 |
|
| 1993 |
Heaton KM, Ju G, Morris DK, Delisio K, Bailon P, Grimm EA. Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor. Cellular Immunology. 147: 167-79. PMID 8462109 DOI: 10.1006/Cimm.1993.1057 |
0.416 |
|
| 1993 |
Koberda J, Grimm EA, Moser RP. Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor beta inhibition of lymphokine-activated killer cell generation. Journal of Cancer Research and Clinical Oncology. 119: 131-6. PMID 8380285 DOI: 10.1007/Bf01229526 |
0.348 |
|
| 1993 |
Heaton KM, Grimm EA. Cytokine combinations in immunotherapy for solid tumors: a review. Cancer Immunology, Immunotherapy : Cii. 37: 213-9. PMID 8348559 DOI: 10.1007/Bf01518513 |
0.394 |
|
| 1993 |
Lazenby AW, Roth JA, Owen-Schaub LB, Grimm EA. IL-1 synergy with IL-2 in the generation of lymphokine activated killer cells is mediated by TNF-alpha and beta (lymphotoxin). Cytokine. 4: 479-87. PMID 1337985 DOI: 10.1016/1043-4666(92)90008-F |
0.432 |
|
| 1992 |
Yang SC, Fry KD, Grimm EA, Roth JA. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 10: 326-35. PMID 1790140 DOI: 10.1097/00002371-199110000-00004 |
0.415 |
|
| 1992 |
Owen-Schaub LB, Yonehara S, Crump WL, Grimm EA. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cellular Immunology. 140: 197-205. PMID 1371242 DOI: 10.1016/0008-8749(92)90187-T |
0.438 |
|
| 1991 |
Owen-Schaub LB, de Mars M, Murphy EC, Grimm EA. IL-2 dose regulates TNF-alpha mRNA transcription and protein secretion in human peripheral blood lymphocytes. Cellular Immunology. 132: 193-200. PMID 2065356 DOI: 10.1016/0008-8749(91)90018-7 |
0.357 |
|
| 1991 |
Grimm EA, Owen-Schaub L. The IL-2 mediated amplification of cellular cytotoxicity. Journal of Cellular Biochemistry. 45: 335-9. PMID 2045426 DOI: 10.1002/Jcb.240450405 |
0.438 |
|
| 1991 |
Grimm EA, Bruner JM, Carinhas J, Köppen JA, Loudon WG, Owen-Schaub L, Steck PA, Moser RP. Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype. Cancer Immunology, Immunotherapy : Cii. 32: 391-9. PMID 1848799 DOI: 10.1007/Bf01741334 |
0.452 |
|
| 1990 |
Crump WL, Owen-Schaub LB, Grimm EA. Molecular identification of the human tumor necrosis factor receptor on interleukin-2-stimulated peripheral blood lymphocytes. Cellular Immunology. 131: 150-8. PMID 2171784 DOI: 10.1016/0008-8749(90)90242-J |
0.34 |
|
| 1990 |
Yang SC, Fry KD, Grimm EA, Roth JA. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha. Archives of Surgery (Chicago, Ill. : 1960). 125: 220-5. PMID 2137327 DOI: 10.1001/Archsurg.1990.01410140098016 |
0.393 |
|
| 1990 |
Yang SC, Owen-Schaub L, Mendiguren-Rodriguez A, Grimm EA, Hong WK, Roth JA, Mountain F. Combination immunotherapy for non-small cell lung cancer The Journal of Thoracic and Cardiovascular Surgery. 99: 8-13. DOI: 10.1016/S0022-5223(19)35625-9 |
0.326 |
|
| 1989 |
Yang SC, Owen-Schaub L, Grimm EA, Roth JA. Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets. Cancer Immunology, Immunotherapy : Cii. 29: 193-8. PMID 2543502 DOI: 10.1007/Bf00199995 |
0.478 |
|
| 1988 |
George RE, Loudon WG, Moser RP, Bruner JM, Steck PA, Grimm EA. In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells. Journal of Neurosurgery. 69: 403-9. PMID 3261328 DOI: 10.3171/Jns.1988.69.3.0403 |
0.414 |
|
| 1988 |
Grimm EA, Crump WL, Durett A, Hester JP, Lagoo-Deenadalayan S, Owen-Schaub LB. TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunology, Immunotherapy : Cii. 27: 53-8. PMID 3260821 DOI: 10.1007/Bf00205758 |
0.408 |
|
| 1988 |
Yagita M, Grimm EA. Current understanding of the lymphokine-activated killer cell phenomenon. Progress in Experimental Tumor Research. 32: 213-26. PMID 3131833 DOI: 10.1159/000414680 |
0.314 |
|
| 1988 |
Owen-Schaub LB, Loudon WG, Yagita M, Grimm EA. Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors. Cellular Immunology. 111: 235-46. PMID 3123071 DOI: 10.1016/0008-8749(88)90066-4 |
0.418 |
|
| 1987 |
Grimm EA. Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality. Biochimica Et Biophysica Acta. 865: 267-79. PMID 3539198 DOI: 10.1016/0304-419X(86)90017-X |
0.372 |
|
| 1987 |
Yagita M, Grimm EA. Inhibition of in vitro LAK generation by OK-432. Cancer Immunology, Immunotherapy : Cii. 23: 207-13. PMID 3491681 DOI: 10.1007/BF00205651 |
0.302 |
|
| 1987 |
Tsudo M, Goldman CK, Bongiovanni KF, Chan WC, Winton EF, Yagita M, Grimm EA, Waldmann TA. The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proceedings of the National Academy of Sciences of the United States of America. 84: 5394-8. PMID 3110786 DOI: 10.1073/Pnas.84.15.5394 |
0.398 |
|
| 1987 |
Jacobs SK, Parham CW, Holcomb B, Ikejiri B, Kornblith PL, Grimm EA. Lymphokine activated killer (LAK) cell mediated killing of human glioma: effect of pretreating glioma with various membrane modifying agents. Journal of Neuro-Oncology. 5: 5-10. PMID 3037036 DOI: 10.1007/Bf00162760 |
0.44 |
|
| 1986 |
Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. Journal of Neurosurgery. 64: 743-9. PMID 3517250 DOI: 10.3171/Jns.1986.64.5.0743 |
0.473 |
|
| 1986 |
Jacobs SK, Melin G, Holcomb B, Parham CW, Kornblith PL, Grimm EA. Lymphokine activated killer (LAK) cell-mediated lysis of murine glioma: trypsin-chymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells. Brain Research. 372: 386-9. PMID 3486696 DOI: 10.1016/0006-8993(86)91150-9 |
0.41 |
|
| 1986 |
Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. Journal of Neurosurgery. 64: 114-7. PMID 3001247 DOI: 10.3171/Jns.1986.64.1.0114 |
0.42 |
|
| 1985 |
Grimm EA, Wilson DJ. The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. Cellular Immunology. 94: 568-78. PMID 3928175 DOI: 10.1016/0008-8749(85)90280-1 |
0.484 |
|
| 1985 |
Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer. 55: 1327-33. PMID 3871657 DOI: 10.1002/1097-0142(19850315)55:6<1327::Aid-Cncr2820550628>3.0.Co;2-O |
0.479 |
|
| 1985 |
Grimm EA, Muul LM, Wilson DJ. The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL. Transplantation. 39: 537-40. PMID 3158107 DOI: 10.1097/00007890-198505000-00016 |
0.401 |
|
| 1985 |
Grimm EA, Rayner AA, Wilson DJ. Human NK resistant tumor cell lysis is effected by IL-2 activated killer cells Advances in Experimental Medicine and Biology. 184: 161-175. PMID 2994409 DOI: 10.1007/978-1-4684-8326-0_11 |
0.368 |
|
| 1985 |
Rayner AA, Grimm EA, Lotze MT, Wilson DJ, Rosenberg SA. Lymphokine-Activated Killer (LAK) Cell Phenomenon. IV. Lysis by LAK Cell Clones of Fresh Human Tumor Cells From Autologous and Multiple Allogeneic Tumors Journal of the National Cancer Institute. 75: 67-75. DOI: 10.1093/Jnci/75.1.67 |
0.456 |
|
| 1984 |
Mazumder A, Eberlein TJ, Grimm EA, Wilson DJ, Keenan AM, Aamodt R, Rosenberg SA. Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer. 53: 896-905. PMID 6692292 DOI: 10.1002/1097-0142(19840215)53:4<896::Aid-Cncr2820530414>3.0.Co;2-E |
0.411 |
|
| 1984 |
Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (New York, N.Y.). 223: 1412-4. PMID 6367046 DOI: 10.1126/Science.6367046 |
0.411 |
|
| 1983 |
Mazumder A, Grimm EA, Rosenberg SA. Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization. Cancer Immunology, Immunotherapy : Cii. 15: 1-10. PMID 6603260 DOI: 10.1007/Bf00199454 |
0.43 |
|
| 1983 |
Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells Journal of Experimental Medicine. 157: 884-892. PMID 6601174 DOI: 10.1084/Jem.157.3.884 |
0.407 |
|
| 1983 |
Grimm EA, Robb RJ, Roth JA, Neckers LM, Lachman LB, Wilson DJ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. The Journal of Experimental Medicine. 158: 1356-61. PMID 6413638 DOI: 10.1084/Jem.158.4.1356 |
0.439 |
|
| 1983 |
Bonavida B, Bradley TP, Grimm EA. Frequency determination of killer cells by a single-cell cytotoxic assay. Methods in Enzymology. 93: 270-80. PMID 6408349 DOI: 10.1016/S0076-6879(83)93049-5 |
0.341 |
|
| 1982 |
Grimm EA, Mazumder A, Rosenberg SA. In vitro growth of cytotoxic human lymphocytes. V. Generation of allospecific cytotoxic lymphocytes to nonimmunogenic antigen by supplementation of in vitro sensitization with partially purified T-cell growth factor. Cellular Immunology. 70: 248-59. PMID 6812964 DOI: 10.1016/0008-8749(82)90326-4 |
0.353 |
|
| 1982 |
Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. The Journal of Experimental Medicine. 155: 1823-41. PMID 6176669 DOI: 10.1084/Jem.155.6.1823 |
0.49 |
|
| 1982 |
Grimm E, Gorelik E, Rosenstein M, Rosenberg S. The lymphokine-activated killer cell phenomenon: In vitro and in vivo studies Cellular Immunology. 70: 409. DOI: 10.1016/0008-8749(82)90427-0 |
0.355 |
|
| 1981 |
Neville ME, Grimm E, Bonavida B. Frequency determination of K cells by a single cell cytotoxic assay. Journal of Immunological Methods. 36: 255-68. PMID 7430654 DOI: 10.1016/0022-1759(80)90131-3 |
0.322 |
|
| 1979 |
Grimm E, Price Z, Bonavida B. Studies on the induction and expression of T cell-mediated immunity. VIII. Effector-target junctions and target cell membrane disruption during cytolysis. Cellular Immunology. 46: 77-99. PMID 314849 DOI: 10.1016/0008-8749(79)90247-8 |
0.37 |
|
| 1976 |
Grimm EA, Silver HK, Roth JA, Chee DO, Gupta RK, Morton DL. Detection of tumor-associated antigen in human melanoma cell line supernatants. International Journal of Cancer. 17: 559-64. PMID 1270174 DOI: 10.1002/Ijc.2910170503 |
0.364 |
|
| Show low-probability matches. |